CO6751239A2 - Compuesto bicíclico - Google Patents

Compuesto bicíclico

Info

Publication number
CO6751239A2
CO6751239A2 CO13149620A CO13149620A CO6751239A2 CO 6751239 A2 CO6751239 A2 CO 6751239A2 CO 13149620 A CO13149620 A CO 13149620A CO 13149620 A CO13149620 A CO 13149620A CO 6751239 A2 CO6751239 A2 CO 6751239A2
Authority
CO
Colombia
Prior art keywords
bicyclic compound
present
compound
obesity
diabetes
Prior art date
Application number
CO13149620A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Makoto Kamata
Tohru Yamashita
Hideki Hirose
Masataka Murakami
Asato Kina
Kazuko Yonemori
Ryo Mizojiri
Ikuo Fujimori
Takuya Fujimoto
Zenichi Ikeda
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6751239A2 publication Critical patent/CO6751239A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona un compuesto que tiene una acción inhibidora de ACC, que es de utilidad como un agente para la prevención o el tratamiento de obesidad, diabetes, y similares y que tiene una eficacia superior.La presente invención se refiere a un compuesto representado por la fórmula (I)en donde cada símbolo es como se define en la memoria descriptiva, o una de sus sales.
CO13149620A 2010-11-30 2013-06-24 Compuesto bicíclico CO6751239A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010266097 2010-11-30
JP2011175330 2011-08-10

Publications (1)

Publication Number Publication Date
CO6751239A2 true CO6751239A2 (es) 2013-09-16

Family

ID=45418740

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13149620A CO6751239A2 (es) 2010-11-30 2013-06-24 Compuesto bicíclico

Country Status (23)

Country Link
US (1) US8729102B2 (es)
EP (1) EP2649062B1 (es)
JP (1) JP5824517B2 (es)
KR (1) KR20140001965A (es)
CN (1) CN103347872B (es)
AR (1) AR084032A1 (es)
AU (1) AU2011337565A1 (es)
BR (1) BR112013013417A2 (es)
CA (1) CA2819400A1 (es)
CL (1) CL2013001520A1 (es)
CO (1) CO6751239A2 (es)
CR (1) CR20130281A (es)
DO (1) DOP2013000118A (es)
EA (1) EA201390794A1 (es)
EC (1) ECSP13012719A (es)
ES (1) ES2536319T3 (es)
MA (1) MA34713B1 (es)
MX (1) MX2013006113A (es)
PE (1) PE20140161A1 (es)
SG (1) SG190925A1 (es)
TW (1) TW201242951A (es)
UY (1) UY33756A (es)
WO (1) WO2012074126A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130094211A (ko) 2010-04-27 2013-08-23 다케다 야쿠힌 고교 가부시키가이샤 바이시클릭 화합물 유도체 및 이의 ａｃｃ 저해제로서의 용도
JPWO2013061962A1 (ja) 2011-10-24 2015-04-02 武田薬品工業株式会社 二環性化合物
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
AU2014262546B2 (en) 2013-05-10 2018-11-08 Gilead Apollo, Llc ACC inhibitors and uses thereof
CN105358154A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
BR112015028214A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
CN105530940A (zh) 2013-09-12 2016-04-27 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途
EA201690888A1 (ru) 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
PL3177612T3 (pl) 2014-08-04 2022-08-08 Nuevolution A/S Opcjonalnie skondensowane pochodne pirymidyny podstawione heterocyklilem, użyteczne w leczeniu chorób zapalnych, metabolicznych, onkologicznych i autoimmunologicznych
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
ES2898965T3 (es) * 2014-08-29 2022-03-09 Chdi Foundation Inc Sondas de formación de imágenes de la proteína Huntingtina
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
CN104447725B (zh) * 2014-10-22 2018-02-02 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
EP3355699B1 (en) * 2015-09-29 2021-03-31 OncoTherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
CN105601626A (zh) * 2015-11-04 2016-05-25 浙江大学 一种含2-取代噁唑啉衍生物的制备方法
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
AR107293A1 (es) 2016-01-05 2018-04-18 Incyte Corp COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
BR112019022320A2 (pt) 2017-04-24 2020-05-26 Tesaro, Inc. Métodos de fabricação de niraparibe
PT3697789T (pt) 2017-10-18 2021-12-31 Incyte Corp Derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3kgama
HRP20240252T1 (hr) 2018-09-05 2024-05-24 Incyte Corporation Kristalni oblici inhibitora fosfoinozitid 3 kinaze (pi3k)
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
DE69828522T2 (de) * 1997-04-30 2005-12-15 Eli Lilly And Co., Indianapolis Antithrombotische mittel
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
DK1285651T3 (da) 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANIN CONCENTRATION HORMONE ANTAGONIST
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
JP4468810B2 (ja) * 2002-07-24 2010-05-26 キューエルティー インコーポレーティッド ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
ZA200503967B (en) 2002-11-01 2006-11-29 Takeda Pharmaceutical Agent for preventing or treating neuropathy
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical PHENOXYALKANSÄUREVERBINDUNG
PE20070338A1 (es) 2005-08-10 2007-04-16 Takeda Pharmaceutical Derivados heterociclicos como agentes terapeuticos para diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20070219258A1 (en) * 2006-02-15 2007-09-20 Keyes Robert F Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
UA95296C2 (uk) 2006-06-27 2011-07-25 Такеда Фармасьютікал Компані Лімітед Конденсовані циклічні сполуки
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical FUSED HETEROCYCLIC COMPOUND
GEP20115241B (en) 2006-10-19 2011-06-10 Takeda Pharmaceutical Indole compound
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
BRPI0807014A2 (pt) 2007-02-09 2014-04-22 Takeda Pharmaceutical Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
KR20130094211A (ko) 2010-04-27 2013-08-23 다케다 야쿠힌 고교 가부시키가이샤 바이시클릭 화합물 유도체 및 이의 ａｃｃ 저해제로서의 용도
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物

Also Published As

Publication number Publication date
CN103347872A (zh) 2013-10-09
CA2819400A1 (en) 2012-06-07
EP2649062B1 (en) 2015-04-08
AR084032A1 (es) 2013-04-17
MX2013006113A (es) 2013-11-01
MA34713B1 (fr) 2013-12-03
TW201242951A (en) 2012-11-01
ES2536319T3 (es) 2015-05-22
CL2013001520A1 (es) 2013-10-18
CR20130281A (es) 2013-10-07
KR20140001965A (ko) 2014-01-07
US20120142714A1 (en) 2012-06-07
AU2011337565A1 (en) 2013-07-11
CN103347872B (zh) 2014-12-24
BR112013013417A2 (pt) 2019-09-24
JP2013545718A (ja) 2013-12-26
WO2012074126A9 (en) 2013-06-06
EP2649062A1 (en) 2013-10-16
SG190925A1 (en) 2013-07-31
US8729102B2 (en) 2014-05-20
WO2012074126A1 (en) 2012-06-07
AU2011337565A2 (en) 2013-07-11
EA201390794A1 (ru) 2013-11-29
ECSP13012719A (es) 2013-12-31
UY33756A (es) 2012-06-29
PE20140161A1 (es) 2014-02-19
JP5824517B2 (ja) 2015-11-25
DOP2013000118A (es) 2013-09-30

Similar Documents

Publication Publication Date Title
CO6751239A2 (es) Compuesto bicíclico
UY35821A (es) Compuesto heterocíclico
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
ECSP15028917A (es) Compuesto heterocíclico
CR20150217A (es) Inhibidores de histona demetilasas
ECSP10010526A (es) Compuesto heterociclico
ECSP12012160A (es) Compuesto heterociclico
CR20110440A (es) Compuestos de piridazinona
CO6640253A2 (es) Derivados de compuesto biciclico y su uso como inhibidores de acc
CR20130024A (es) Compuestos heterocíclicos fusionados
DOP2016000253A (es) Nuevos compuestos
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO2019012125A2 (es) Inhibidores ip6k
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
CO6321240A2 (es) Compuestos de anillo fusionados como activadores de glucocinasa
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
DOP2013000051A (es) Compuestos heterociclico y sus usos
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112016012505A2 (pt) composto para tratamento de hipoglicemia severa
ECSP099836A (es) Macrociclos y sus usos
BR112016012067A2 (pt) composto para o tratamento de hipo¬glicemia grave
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
AR098670A1 (es) Inhibidor de sglt1

Legal Events

Date Code Title Description
FC Application refused